Cheng Qi

Chengqi Biotech is a pioneering biotechnology company headquartered in Suzhou, China, dedicated to the development of next-generation RNA editing therapeutics. The company's proprietary LEAPER platform utilizes endogenous ADAR enzymes to achieve precise A-to-I RNA editing, offering a potentially safer alternative to DNA-based gene editing by avoiding permanent genomic changes and the delivery of exogenous proteins. Founded by Dr. Chengqi Yi of Peking University, the company is leveraging this technology to address a variety of genetic diseases, including Alpha-1 antitrypsin deficiency and Hurler syndrome. Chengqi Biotech has secured significant backing from prominent investors such as IDG Capital and GL Ventures to advance its pre-clinical pipeline toward clinical trials.